Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunology
Biotech
Formation Bio makes $605M play for Lynk's TYK2 inhibitor
Lynk’s TYK2 program will be developed by Formation’s freshly formed subsidiary, dubbed Bleecker Bio.
Gabrielle Masson
Dec 10, 2025 10:27am
Pfizer Ventures gets behind Chinese biotech's $100M series A
Dec 5, 2025 4:20am
Biogen returns to its roots with a West Coast immunology outpost
Nov 18, 2025 12:25pm
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Oct 24, 2025 9:15am
Nilo launches with $101M and mission to harness neural circuits
Oct 8, 2025 9:55am
AstraZeneca, Algen Biotechnologies pen $555M AI pact
Oct 6, 2025 8:00am
